Drug Type Biological products |
Synonyms |
Target |
Mechanism CTLA4 inhibitors(Cytotoxic T-Lymphocyte-Associated Antigen 4 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hepatocellular Carcinoma | Phase 2 | CN | 15 Apr 2024 | |
Liver Cancer | Phase 2 | CN | 13 Jul 2023 | |
Melanoma | Phase 2 | CN | 14 Mar 2023 | |
Advanced Malignant Solid Neoplasm | Preclinical | CN | 10 Sep 2020 | |
Advanced Malignant Solid Neoplasm | Preclinical | CN | 10 Sep 2020 |
Phase 1/2 | 29 | KD6001 + Toripalimab | (eqijxikwhq) = 26 (89.7%) pts had treatment-related adverse events (TRAEs), with ≥Gr 3 TRAEs occurring in 3 (10.3%) pts and were well manageable. All other TRAEs were Gr 1 or 2. There were no death events due to TRAEs. ehejhifkjh (sxgqmyyycc ) | Positive | 24 May 2024 | ||
Phase 1 | - | (lvqagsxwfj) = npivoyqiyo eirkrqcgmw (wbporsggdc ) View more | Positive | 24 May 2024 |